Celldex Therapeutics (CLDX) Given Daily News Impact Rating of 0.27

Media coverage about Celldex Therapeutics (NASDAQ:CLDX) has been trending positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.27 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 47.7225626030024 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news stories that may have impacted Accern’s rankings:

How to Become a New Pot Stock Millionaire

CLDX stock opened at $2.35 on Friday. The stock has a market capitalization of $344.22, a PE ratio of -3.18 and a beta of 2.63. Celldex Therapeutics has a 52 week low of $2.20 and a 52 week high of $3.75.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.08. The company had revenue of $3.50 million for the quarter, compared to the consensus estimate of $1.49 million. Celldex Therapeutics had a negative return on equity of 44.64% and a negative net margin of 730.06%. The firm’s revenue was up 87.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.30) EPS. equities research analysts anticipate that Celldex Therapeutics will post -0.72 EPS for the current year.

CLDX has been the topic of several recent research reports. HC Wainwright set a $10.00 target price on Celldex Therapeutics and gave the stock a “buy” rating in a report on Friday, February 9th. WBB Securities reaffirmed a “buy” rating and set a $10.00 target price on shares of Celldex Therapeutics in a report on Wednesday, December 6th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $9.00 target price on shares of Celldex Therapeutics in a report on Wednesday, March 7th. BidaskClub raised Celldex Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 6th. Finally, Leerink Swann reaffirmed a “market perform” rating and set a $3.00 target price (down from $4.00) on shares of Celldex Therapeutics in a report on Thursday, March 8th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $6.38.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3296611/celldex-therapeutics-cldx-given-daily-news-impact-rating-of-0-27.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Insider Buying and Selling by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Fresenius SE & Co KGaA  Given a €82.00 Price Target by Nord/LB Analysts
Fresenius SE & Co KGaA Given a €82.00 Price Target by Nord/LB Analysts
Investment Analysts’ Updated EPS Estimates for April, 25th
Investment Analysts’ Updated EPS Estimates for April, 25th
Omnicell Technologies  to Release Quarterly Earnings on Wednesday
Omnicell Technologies to Release Quarterly Earnings on Wednesday
Leggett & Platt  to Release Earnings on Thursday
Leggett & Platt to Release Earnings on Thursday
S&P Global  Set to Announce Quarterly Earnings on Thursday
S&P Global Set to Announce Quarterly Earnings on Thursday
UBS Analysts Give Lanxess  a €73.00 Price Target
UBS Analysts Give Lanxess a €73.00 Price Target


© 2006-2018 Ticker Report. Google+.